Statera BioPharma (STU:7CB) ROE % Adjusted to Book Value: 0.00% (As of Sep. 2022)


What is Statera BioPharma ROE % Adjusted to Book Value?

Statera BioPharma STU:7CB 20 ROE % Adjusted to Book Value is 0.00% as of Sep. 2022. GuruFocus rates STU:7CB with a GF Score™ of 20/100. The stock has 1 warning sign investors should review.

Statera BioPharma's ROE % for the quarter that ended in Sep. 2022 was 0.00%. Statera BioPharma's PB Ratio for the quarter that ended in Sep. 2022 was N/A. Statera BioPharma's ROE % Adjusted to Book Value for the quarter that ended in Sep. 2022 was N/A.

Statera BioPharma ROE % Adjusted to Book Value Related Terms

Statera BioPharma ROE % Adjusted to Book Value Historical Data

* Premium members only.

The historical data trend for Statera BioPharma's ROE % Adjusted to Book Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Statera BioPharma ROE % Adjusted to Book Value Chart

Statera BioPharma Annual Data
Trend Dec19 Dec20 Dec21
ROE % Adjusted to Book Value
0.00 0.00 0.00

Statera BioPharma Quarterly Data
Dec19 Mar20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22
ROE % Adjusted to Book Value Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

STU:7CB vs NRBO, PALI, BLCM: ROE % Adjusted to Book Value Comparison

For the Biotechnology subindustry, Statera BioPharma's ROE % Adjusted to Book Value, along with its competitors' market caps and ROE % Adjusted to Book Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Statera BioPharma ROE % Adjusted to Book Value vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Statera BioPharma's ROE % Adjusted to Book Value distribution charts can be found below:

* The bar in red indicates where Statera BioPharma's ROE % Adjusted to Book Value falls into.


Statera BioPharma ROE % Adjusted to Book Value Calculation

Statera BioPharma's ROE % Adjusted to Book Value for the fiscal year that ended in Dec. 2021 is calculated as

ROE % Adjusted to Book Value=ROE % / PB Ratio
=0.00% / N/A
=N/A

Statera BioPharma's ROE % Adjusted to Book Value for the quarter that ended in Sep. 2022 is calculated as

ROE % Adjusted to Book Value=ROE % / PB Ratio
=0.00% / N/A
=N/A

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a ROE % Adjusted to Book Value of 0.00% mean?
Statera BioPharma (STU:7CB) has a ROE % Adjusted to Book Value of 0.00% as of Sep. 2022. Return on equity adjusted to book is the ratio of return on equity to price-book ratio. View historical data on Statera BioPharma and its competitors.
Is Statera BioPharma's ROE % Adjusted to Book Value too high?
Statera BioPharma's current ROE % Adjusted to Book Value is 0.00%. Overall, Statera BioPharma has a GF Score™ of 20/100, reflecting its overall financial health beyond just this single metric.
How does Statera BioPharma's ROE % Adjusted to Book Value compare to NRBO and PALI?
Statera BioPharma's ROE % Adjusted to Book Value of 0.00% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROE % Adjusted to Book Value for a Biotechnology company?
A good ROE % Adjusted to Book Value depends on the Biotechnology industry context. However, ROE % Adjusted to Book Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROE % Adjusted to Book Value mean?
A high ROE % Adjusted to Book Value can signal that a stock is expensive relative to its fundamentals. Return on equity adjusted to book is the ratio of return on equity to price-book ratio. View historical data on Statera BioPharma and its competitors. Statera BioPharma's current ROE % Adjusted to Book Value is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Statera BioPharma stock overvalued right now?
Statera BioPharma (STU:7CB) has a current ROE % Adjusted to Book Value of 0.00%. The current ROE % Adjusted to Book Value is 0.00%. Statera BioPharma's overall GF Score™ is 20/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROE % Adjusted to Book Value calculated?
ROE % Adjusted to Book Value is calculated from a company's financial statements. For Statera BioPharma (STU:7CB), the current ROE % Adjusted to Book Value is 0.00% as of Sep. 2022. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Statera BioPharma Business Description

Address 2580 East Harmony Road, Suite 316, Fort Collins, CO, USA, 80528
Statera BioPharma Inc is a pre-clinical and clinical biopharmaceutical company developing multiple product candidates to address unmet medical needs for use in diseases involving immune system dysfunction. Its proprietary platform of Toll-like receptor drug candidates has applications in mitigation of radiation injury, mitigation of T-cell exhaustion, inflammation, T-cell exhaustion, immune system dysfunction, oncology, infection and neutropenia.